Completion of a single-center phase I study of the safety and pharmacokinetics of CPL207280

We have just completed a phase I study of safety and pharmacokinetics (part B) of an innovative therapy that could be used in the treatment of diabetes and metabolic diseases. The product was administered to approximately 32 healthy volunteers as tablets in ascending doses with single administration in the first part of the study and multiple administrations in the double-blind second part.

Due to the global COVID-19 epidemic, the study was conducted using instructions and procedures in line with the guidelines of the Ministry of Health, Sanitary-epidemiological station, WHO (World Health Organization) and EMA (European Medicines Agency).

The tested compound belongs to the newest generation of drugs used in the treatment of diabetes and metabolic diseases. The study confirmed that the drug has a very good safety profile in toxicological and preclinical studies, unlike other drugs in this class. In the case of normal blood glucose levels, the drug does not lower the glucose level, which prevents the occurrence of hypoglycemia.

 The results of the study confirmed that the new therapy is effective in regulating blood glucose levels and could be used in the treatment of diseases such as type II diabetes.

Go back

News

6th anniversary

This week we celebrate our 6th anniversary. Together with our CEO, clinical team and company's friends, we had a pleasure of being at Aga Zaryan's concert and fancy diner.

Read more …

Webinar

We are constantly improving our knowledge to assure the best possible quality of our services.

Read more …

Medical Guide Where to Treat 2022

On 29th of April, a special thematic supplement was published in the Polska The Times and Miasto.pl newspaper - Medical Guide Where to Treat 2022...

Read more …

BRG Support for Ukraine

We are deeply moved and concerned by the events in Ukraine. As a clinical site, focused on the development of medicine and helping other people,...

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲